Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
1998 1
1999 4
2000 3
2001 2
2002 2
2003 4
2004 2
2005 1
2006 1
2012 1
2013 2
2016 1
2017 1
2018 1
2019 1
2020 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial.
Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. Bennouna J, et al. Lancet Oncol. 2013 Jan;14(1):29-37. doi: 10.1016/S1470-2045(12)70477-1. Epub 2012 Nov 16. Lancet Oncol. 2013. PMID: 23168366 Clinical Trial.
Multicenter phase II feasibility trial of high-dose tamoxifen in patients with refractory or relapsed multiple myeloma.
Decaudin D, Etienne MC, De Cremoux P, Maciorowski Z, Vantelon JM, Voog E, Urien S, Tran-Perennou C, Renée N, Vielh P, Némati F, Pouillart P. Decaudin D, et al. Among authors: vantelon jm. J Natl Cancer Inst. 2004 Apr 21;96(8):636-7. doi: 10.1093/jnci/djh108. J Natl Cancer Inst. 2004. PMID: 15100346 Clinical Trial. No abstract available.
Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma.
Decaudin D, Vantelon JM, Bourhis JH, Farace F, Bonnet ML, Guillier M, Greissenger N, Marracho MC, Assari S, Bennaceur AL, Némati F, Michon J, Turhan AG, Boccaccio C. Decaudin D, et al. Among authors: vantelon jm. Bone Marrow Transplant. 2004 Dec;34(12):1089-93. doi: 10.1038/sj.bmt.1704675. Bone Marrow Transplant. 2004. PMID: 15489877 Clinical Trial.
Prognostic value of the age-adjusted International Prognostic Index in chemosensitive recurrent or refractory non-Hodgkin's lymphomas treated with high-dose BEAM therapy and autologous stem cell transplantation.
Jabbour E, Peslin N, Arnaud P, Ferme C, Carde P, Vantelon JM, Bocaccio C, Bourhis JH, Koscielny S, Ribrag V. Jabbour E, et al. Among authors: vantelon jm. Leuk Lymphoma. 2005 Jun;46(6):861-7. doi: 10.1080/10428190500054350. Leuk Lymphoma. 2005. PMID: 16019530
26 results